acute respiratory distress syndrome
Conditions
Interventions
Test group:Silvelestat sodium for injection was administered intravenously for 7 days
Control group:Silvelestat sodium placebo was administered intravenously for 7 days
Sponsors
China-japan friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Age =18 years old (2) It conforms to the diagnostic criteria of ARDS Berlin (3) ARDS caused by pulmonary factors (4) 100mmHg < oxygenation index =300mmHg (5) Diagnosis of ARDS < 72 hours
Exclusion criteria
Exclusion criteria: (1) Pregnant and lactating women (2) ARDS caused by extrapulmonary factors (3) Brain death (4) Terminal stage of tumor or other diseases (5) Treatment was abandoned after admission to ICU (6) Severe chronic lung disease (with chronic respiratory failure) (7) Congestive heart failure (8) Respiratory cardiac arrest (9) Severe hemodynamic instability (10) Refuse to participate in this study or have joined other researchers (11) Hospice (12) Extrapulmonary SOFA=6 points (13) Ulinastatin, thymphatin and Xuebijin were used within 72 hours before enrollment (14) glucocorticoid use =1mg/kg/d during the first 7 days of enrollment (15) Known allergy to cilverestat sodium or excipients and to other substances involved in the examination (16) Patients who had used an IL-6 antagonist (e.g., tozizumab) or a JAK inhibitor in the week prior to enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Oxygenation index; | — |
Secondary
| Measure | Time frame |
|---|---|
| inflammatory factor;lung injury score;Acute Physiology and Chronic Health Evaluation. (APACHE II scoring);Sequential Organ Failure Assessment scoring. (SOFA scoring); | — |
Countries
China
Contacts
Public ContactZhanQingyuan
China-japan Friendship Hospital
Outcome results
None listed